Current status and trends of immune-related adverse events in lung cancer treated with immune checkpoint inhibitors: a bibliometric analysis of the past decade (2016–2025) - Scorecard - MDSpire

Current status and trends of immune-related adverse events in lung cancer treated with immune checkpoint inhibitors: a bibliometric analysis of the past decade (2016–2025)

  • By

  • Bing Guo

  • Ge Zhang

  • Shengpeng Sang

  • Xianfen Ma

  • Huanpeng Qi

  • June 2, 2026

  • 0 min

Share

Clinical Scorecard: Trends and Current Insights on Immune-Related Adverse Events in Lung Cancer Patients Receiving Immune Checkpoint Inhibitors: A Decadal Bibliometric Review (2016–2025)

At a Glance

CategoryDetail
ConditionLung Cancer
Key MechanismsImmune checkpoint inhibitors (ICIs) induce immune-related adverse events (irAEs) affecting multiple organ systems.
Target PopulationPatients with lung cancer receiving ICIs.
Care SettingOncology clinics and research institutions.

Key Highlights

  • Continuous increase in publications on irAEs from 2016 to 2025.
  • China leads in publication volume, while the US has high betweenness centrality in collaboration.
  • Major research hotspots include organ-specific high-risk irAEs and biomarker-related studies.
  • High-grade irAEs such as immune-related pneumonia pose significant risks in lung cancer patients.

Guideline-Based Recommendations

Diagnosis

  • Early identification of irAEs is crucial for effective management.

Management

  • Follow guidelines from ASCO, ESMO, and SITC for irAE management.

Monitoring & Follow-up

  • Monitor for high-grade irAEs, particularly immune-related pneumonia.

Risks

  • Lung cancer patients have a higher risk of developing irAEs and associated mortality.

Patient & Prescribing Data

Lung cancer patients undergoing treatment with ICIs.

Combination immunotherapy and monitoring for pulmonary toxicity are key focus areas.

Clinical Best Practices

  • Implement personalized intervention strategies for irAEs.
  • Utilize bibliometric analyses to identify research trends and gaps.

Related Resources & Content

Original Source(s)

Current status and trends of immune-related adverse events in lung cancer treated with immune checkpoint inhibitors: a bibliometric analysis of the past decade (2016–2025)

  • by Bing Guo, Ge Zhang, Shengpeng Sang, Xianfen Ma, Huanpeng Qi

  • June 2, 2026

Related Content

Perioperative Apalutamide in High-Risk Localized or Locally Advanced Prostate Cancer Reduces Risk of Metastasis and Death

High-risk localized and locally advanced prostate cancer patients treated with apalutamide — a next generation neoadjuvant androgen-receptor pathway inhibitor (ARPI) — plus hormone therapy before and after prostate cancer surgery resulted in more major pathologic responses and reduced the risk of metastasis or death, meeting both primary endpoints, in an international phase 3 clinical trial led by principal investigator Mary-Ellen Taplin, MD, medical oncologist at Dana-Farber Cancer Institute, and Adam Kibel, MD, chair of the Department of Urology at Mass General Brigham.

  • by

  • June 1, 2026

  • 4 min
Case Report: Intramedullary solitary fibrous tumor at the C7-T1 level diagnosed by STAT6 and treated with maximal safe resection

Effectiveness of a culturally adapted psychoeducational intervention for family caregivers of children with hematologic malignancy: a randomized controlled trial